Study on the treatment of diabetic foot ulcer with nano-level platelet-enriched plasma

Study on the treatment of diabetic foot ulcer with gel derived from nano-platelet vesicles

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046708

Enrollment

Unknown

Registered

2021-05-27

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Interventions

Control group:Debridement

Experimental group:Debridement + gel covering therapy derived from nanoplatelet vesicles

Eligibility

Sex/Gender

All

Age

21 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Diabetes; 2. Plantar ulcer > 0.5 cm^2 (the size after debridement is 1-16 cm2); 3. Neuropathy; 4. Aged at least 21 years; 5. Wound duration > 4 weeks; 6. Glycated hemoglobin <= 13.0%.

Exclusion criteria

Exclusion criteria: 1. Active cellulitis; 2. Osteomyelitis; 3. Gangrene; 4. Insufficient blood supply (ankle-brachial index ABI 1.3); 5. Revascularization in the last 6 weeks (ipsilateral lower extremity); 6. Take any experimental drugs or apply topically to the wound 4 weeks before the study; 7. Non-diabetic etiological ulcers and major medical conditions that can impair wound healing, such as aplastic anemia, liver disease, scleroderma, malignant tumors or immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
Wound area;RNA seq;Immunofluorescence;	—

Countries

China

Contacts

Public ContactLin Xianfeng

Sir Run Run Shaw Hospital, Medical College of Zhejiang University

xianfeng_lin@126.com+86 15268843719

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026